BioHarvest Sciences Inc. has announced a new contract through its Botanical Synthesis CDMO Services division to develop a plant-based fragrance compound. The agreement, which includes milestone-based payments and a non-disclosure agreement for Stage 1, expands BioHarvest's platform into the fragrance market. Utilizing its advanced AI-assisted research capabilities, the company identified specific plant species to develop a cell bank for efficient production of fragrance molecules. Stage 1 will use BioHarvest's proprietary Botanical Synthesis platform to replicate and multiply the plant's targeted cells. A successful outcome could lead to Stage 2, involving production in liquid media, paving the way for future manufacturing. CEO Ilan Sobel highlighted the contract as validation of the platform's ability to deliver scalable solutions while conserving threatened plant species.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.